Digestive Diseases and Sciences

, Volume 28, Issue 4, pp 365–370

Candida esophagitis

  • Robert Mathieson
  • Sudhir K. Dutta
Review Article


Candida esophagitis is being increasingly recognized in the practice of clinical gastroenterology. The widespread use of corticosteroids, immunosuppressive drugs, and cancer chemotherapy, combined with the frequent use of endoscopy for the evaluation of esophageal symptoms, often leads to the identification ofCandida infection in this part of the gastrointestinal tract. The salient clinical features ofCandida esophagitis include odynophagia and dysphagia, although gastrointestinal bleeding may occasionally be the sole presenting symptom. While the radiological signs ofCandida esophagitis are nonspecific, the endoscopic appearance is quite characteristic. Demonstration of tissue invasion by fungal mycelia on mucosal biopsy of the esophagus is diagnostic. The role of serology in the diagnosis ofCandida esophagitis is not well defined. Oral nystatin therapy has been extensively used to controlCandida infection of the esophagus. More recently amphotericin-B, 5-fluorocytosine and imidazole derivatives have been effectively used to treat recalcitrant cases ofCandida esophagitis.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sheft D, Shrago G: Esophangeal moniliasis: The spectrum of the disease. J Am Med Assoc 213:1859–1862, 1970Google Scholar
  2. 2.
    Folb P, Trounce J: Immunological aspects ofCandida infection complicating steroid and immunosuppressive therapy. Lancet 2:1112–1114, 1970Google Scholar
  3. 3.
    Eras P, Goldstein M, Sherlock P:Candida infections of the gastrointestinal tract. Medicine 51:367–379, 1972Google Scholar
  4. 4.
    Jensen K, Stenderup A, Thompson JT, Thomsen J, Bichel J: Esophageal moniliasis in malignant neoplastic disease. Acta Med Scand 175:455–459, 1964Google Scholar
  5. 5.
    Kodsi B, Wickremesinghe P, Kozinn P, Kadirawelpillai I, Goldberg P:Candida esophagitis: A prospective study of 27 cases. Gastroenterology 71:715–719, 1976Google Scholar
  6. 6.
    Carter E, Rajendra G, Schuster M: Monilial and herpetic esophagitis in oncology patients. Gastroenterology 68:1045, 1975 (abstract)Google Scholar
  7. 7.
    Cohen R, Roth F, Delgado E, et al: Fungal flora of the normal human small and large intestine. N Engl J Med 280:638–641, 1969Google Scholar
  8. 8.
    Gorbach S, Nahas L, Lerner P, Weinstein L: Studies of intestinal microflora I. Gastroenterology 53:845–855, 1967Google Scholar
  9. 9.
    Gorbach S, Plaut A, Nahas L, Weinstein L: Studies of intestinal microflora II. Gastroenterology 53:856–867, 1967Google Scholar
  10. 10.
    Dutta S, Al-Ibrahim M: Immunological studies in acute pseudomembraneous esophageal candidiasis. Gastroenterology 75:292–296, 1978Google Scholar
  11. 11.
    Odds FC:Candida and Candidasis: Baltimore, University Park Press, 1979, pp 189–208, 228–244Google Scholar
  12. 12.
    Katzenstein A, Maksem J:Candida infection of gastric ulcers.Am J Clin Pathol 71:137–141, 1979Google Scholar
  13. 13.
    Olin R, Poindexter M: Familial idiopathic hypoparthyroidism. Minn Med 55:701–704, 1972Google Scholar
  14. 14.
    Montes L, Pittman C, Moore W, et al: Chronic mucocutaneous candidiasis: Influence of thyroid status. J Am Med Assoc 221:156–159, 1972Google Scholar
  15. 15.
    Kirkpatrick C: Chronic mucocutaneous candidiasis: Model-building in cellular immunity. Ann Intern Med 74:955–977, 1971Google Scholar
  16. 16.
    Hermans P, Urlich J, Markowitz H: Chronic mucocutaneous candidiasis as a surface expression of deep-seated abnormalities. Am J Med 47:503–519, 1969Google Scholar
  17. 17.
    Quie P, Chilgren R: Acute disseminated and chronic mucocutaneous candidiasis. Semin Hematol 8:227–242, 1971Google Scholar
  18. 18.
    Niethammer D, Heinze E, Teller W, Kleihauer E, Wildfeuer A, Haferkamp O: Impairment of granulocyte function in juvenile diabetes. Klin Wochenschr 53:1057–1060, 1975Google Scholar
  19. 19.
    Lehrer RI: Functional aspects of a second mechanism of candidacidal activity by human neutrophils. J Clin Invest 51:2566–2572, 1972Google Scholar
  20. 20.
    Mahmoud A, Warren K, Rodman H, Mandel M: Effects of diabetes mellitus on cellular immunity. Surg Forum 26:548–550, 1975Google Scholar
  21. 21.
    Seligmann E: Virulence enhancement ofC. albicans by antibiotics and cortisone. Proc Soc Exp Biol Med 83:778–781, 1953Google Scholar
  22. 22.
    Umenai T, Konno J, Ishida A: Systemic candidiasis fromC. albicans colonizing the gastrointestinal tract. Experientia 35:1327–1332, 1979Google Scholar
  23. 23.
    Oblack D, Schwarz J, Holder I: Enhancement of tissue damage byCandida albicans in cortisone or nitrogen mustard-treated mice. Can J Microbiol 28:1015–1020, 1979Google Scholar
  24. 24.
    Holt H:Candida infection of the esophagus. Gut 9:227–231, 1968Google Scholar
  25. 25.
    Orringer M, Sloan H: Monilial esophagitis: An increasingly frequent cause of esophageal stenosis. Ann Thorac Surg 26:364–374, 1974Google Scholar
  26. 26.
    Campero A, Campbell A: Complete esophageal obstruction due to monilial infections. Aust NZ J Surg 43:244–246, 1973Google Scholar
  27. 27.
    Kelvin F, Clark W, Thompson W, Hauch T: Chronic esophageal stricture due to moniliasis. Br J Radiol 51:826–828, 1978Google Scholar
  28. 28.
    Ott D, Gelfand D: Esophageal stricture secondary to candidiasis. Gastrointest Radiol 2:323–325, 1978Google Scholar
  29. 29.
    Kozinn P, Taschdjian C: Enteric candidiasis: Diagnosis and clinical considerations. Pediatrics 30:71–85, 1962Google Scholar
  30. 30.
    Moses H, Cheatham W: The frequency and significance of human herpetic esophagitis. Lab Invest 6:663–669, 1963Google Scholar
  31. 31.
    Kozinn P, Taschdjian C:Candida albicans: Saprophyte or pathogen. J Am Med Assoc 198:190–192, 1966Google Scholar
  32. 32.
    Jones S, Brennan M, Knudsin R:Candida serology: An aid in diagnosis of deep organ candidiasis. J Surg Res 14:235–237, 1973Google Scholar
  33. 33.
    Filice G, Yu B, Armstrong D: Immunodiffusion and agglutination tests forCandida in patients with neoplactic disease: Inconsistent correlation of results with invasive infections. J Infect Dis 135:349–357, 1977Google Scholar
  34. 34.
    Bacon P, Davidson C, Smith B: Antibodies toCandida and autoantibodies in subacute bacterial endocarditis. Q J Med 43:537–550, 1974Google Scholar
  35. 35.
    Murray I, Buckley H, Turner G: Serological evidence ofCandida infection after open heart surgery. J Med Microbiol 2:463–469, 1969Google Scholar
  36. 36.
    Taschdjian C, Seeling M, Kozinn P: Serological diagnosis ofCandida infection. Crit Rev Clin Lab Sci 4:19–60, 1973Google Scholar
  37. 37.
    Stanley V, Hurley R:Candida precipitins in pregnant women: Validity of test-system used. J Clin Pathol 27:66–69, 1974Google Scholar
  38. 38.
    Kozinn P, Taschdjian M, Goldberg P, Protzmann W, Mackenzie D, Remington JS, Anderson S, Seelig M: Efficiency of serologic tests in the diagnosis of systemic candidiasis. Am J Clin Pathol 70:893–898, 1978Google Scholar
  39. 39.
    Weiner M, Yount W: Mannan antigenemia in the diagnosis of invasiveCandida infection. J Clin Invest 58:1045–1053, 1976Google Scholar
  40. 40.
    Weiner M, Coats-Stephen M: Immunodiagnosis of systemic candidiasis: Mannan antigenemia detected by radioimmunossay in experimental and human infections. J Infect Dis 140:989–993, 1979Google Scholar
  41. 41.
    Segal E, Berg R, Pizzo P, Bennett J: Detection ofCandida antigen in sera of patients with candidiasis by an enzymelinked immunoabsorbed assay-inhibition technique. J Clin Microbiol 10:116–118, 1979Google Scholar
  42. 42.
    Kinksy S: Nystatin binding by protoplast and a particulate fraction ofNeurospora crassa and a basis for the selective toxicity of polyene antifungal antibiotics. Proc Natl Acad Sci USA 48:1049–1056, 1962Google Scholar
  43. 43.
    Gilman AG, Goodman S, Gilman A: The Pharmacological Basis of Therapeutics, 6th ed. New York, Macmillian 1980, pp 1232–1238Google Scholar
  44. 44.
    Medoff G, Dismukes W, Meade R, Moses J: A new therapeutic approach toCandida infections. Arch Intern Med 130:241–245, 1972Google Scholar
  45. 45.
    Steer P, Marks M, Klite P, Eickhoff T: 5-Fluorocytosine: An oral antifungal compound. Ann Intern Med 76:15–22, 1972Google Scholar
  46. 46.
    Vandevelde A, Mauceri A, Johnson J: 5-Fluorocytosine in the treatment of mycotic infections. Ann Intern Med 77:43–51, 1972Google Scholar
  47. 47.
    Koechlin B, Rubio F, Palmer S, Gabriel T, Duschinsky R: The metabolism of 5-fluorocytosine-214C and cytosine-14C in man. Biochem Pharmacol 15:435–446, 1966Google Scholar
  48. 48.
    Rutgeerts L, Verhaegen H: Intravenous micronazole in the treatment of chronic esophageal candidiasis. Gastroenterology 72:316–318, 1977Google Scholar
  49. 49.
    Tytgat G, Surachno S, DeGroot W, Schellekens P: A case of chronic oropharyngeal-esophageal candidiasis with immunological deficiency: Successful treatment with micronazole. Gastroenterology 72:536–540, 1977Google Scholar
  50. 50.
    Van den Bossche H: Biochemical effects of miconazole on fungi. I. Effects on the uptake and/or utilization of purines, pyrimidines, nucleosides, amino acids and glucose byCandida albicans. Biochem Pharmacol 23:887–899, 1974Google Scholar
  51. 51.
    DeNollin S, Borgers M: The ultrastructure ofCandida albicans afterin vitro treatment with miconazole. Sabouraundia 12:341–351, 1974Google Scholar
  52. 52.
    Feinstein V, Bodey G: Cardiorespiratory toxicity due to miconazole. Ann Intern Med 93:432–433, 1980Google Scholar
  53. 53.
    Graybill J, Drutz D: Ketoconazole: A major innovation for treatment of fungal disease. Ann Intern Med 93:921–923, 1980Google Scholar

Copyright information

© Digestive Disease Systems, Inc 1983

Authors and Affiliations

  • Robert Mathieson
    • 1
  • Sudhir K. Dutta
    • 1
  1. 1.Division of Gastroenterology, Department of Medicine, Veterans Administration Medical CenterUniversity of Maryland School of MedicineBaltimore

Personalised recommendations